Modulation of interactions of neuroblastoma cell lines
with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a

Horwacik,Irena; Rokita,Hanna

doi:10.3892/ijo.2017.3959

Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a

Authors:
- Irena Horwacik
- Hanna Rokita
View Affiliations

Affiliations: Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland
Published online on: April 7, 2017 https://doi.org/10.3892/ijo.2017.3959
Pages: 1899-1914

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies. We have recently shown that some neuroblastoma cell lines are sensitive to direct cytotoxicity of the anti-GD2 mouse monoclonal antibody 14G2a (mAb). For IMR-32 and LA-N-1 cell lines, treatment with the 14G2a mAb induced evident changes in appearance such as cell rounding, aggregation, loose contact with culture plastic, or detachment. Such findings prompted us to investigate whether modulation of attachment of neuroblastoma cells to extracellular matrix (ECM) proteins can affect their sensitivity to the 14G2a mAb treatment. First, using ultra-low attachment plates, we show that survival of the IMR-32, LA-N-1, LA-N-5, CHP-134 and Kelly cells depends on attachment. Next, we compared cellular ATP levels of the cell lines treated with the 14G2a mAb using uncoated, fibronectin-, collagen IV-coated surfaces to show that the ECM proteins slightly modulate sensitivity of the cell lines to the mAb. Then, we characterized presence of selected integrin subunits or their complexes on the cell surface. Finally, we applied small molecule inhibitors of selected integrin complexes: obtustatin (inhibiting α1β1 heterodimer), BIO 1211 (inhibiting active α4β1 heterodimer), cilengitide and SB273005 (inhibitors of αVβ3, αVβ5 heterodimers) to verify their effects on attachment of cell lines, cellular ATP levels, and in some experiments activities of apoptosis-executing caspase-3 and -7, for the compounds used alone or in combination with the 14G2a mAb. We characterized levels of total FAK (focal adhesion kinase), p-FAK (Tyr397) in IMR-32 cells treated with BIO 1211, and in LA-N-5, Kelly and SK-N-SH cells treated with SB273005. Our results extend knowledge on factors influencing cytotoxicity of 14G2a.

View Figures

View References

1	Cheung NK and Dyer MA: Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 13:397–411. 2013. View Article : Google Scholar : PubMed/NCBI
2	Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB and Matthay KK: Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol. 23:6474–6480. 2005. View Article : Google Scholar : PubMed/NCBI
3	Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al: The genetic landscape of high-risk neuroblastoma. Nat Genet. 45:279–284. 2013. View Article : Google Scholar : PubMed/NCBI
4	Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO and Reaman GH: Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol. 28:2625–2634. 2010. View Article : Google Scholar : PubMed/NCBI
5	Navid F, Santana VM and Barfield RC: Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets. 10:200–209. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hoy SM: Dinutuximab: A review in high-risk neuroblastoma. Target Oncol. 11:247–253. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al Children's Oncology Group: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 363:1324–1334. 2010. View Article : Google Scholar : PubMed/NCBI
8	Horwacik I and Rokita H: Targeting of tumor-associated ganglio-sides with antibodies affects signaling pathways and leads to cell death including apoptosis. Apoptosis. 20:679–688. 2015. View Article : Google Scholar : PubMed/NCBI
9	Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frikeche J, Alvarez-Rueda N, Bougras G, Aubry J, Paris F, et al: Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett. 333:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
10	Horwacik I, Durbas M, Boratyn E, Węgrzyn P and Rokita H: Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett. 341:248–264. 2013. View Article : Google Scholar : PubMed/NCBI
11	Durbas M, Horwacik I, Boratyn E, Kamycka E and Rokita H: GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines. Int J Oncol. 47:1143–1159. 2015.PubMed/NCBI
12	Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
13	Bouvard D, Pouwels J, De Franceschi N and Ivaska J: Integrin inactivators: Balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol. 14:430–442. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jin H and Varner J: Integrins: Roles in cancer development and as treatment targets. Br J Cancer. 90:561–565. 2004. View Article : Google Scholar : PubMed/NCBI
15	Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, et al Etaracizumab Melanoma Study Group: A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α_vβ₃, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer. 116:1526–1534. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, et al: A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 121:273–279. 2011. View Article : Google Scholar : PubMed/NCBI
17	Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, et al European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): A multi-centre, randomised, open-label, phase 3 trial. Lancet Oncol. 15:1100–1108. 2014. View Article : Google Scholar : PubMed/NCBI
18	Young SA, McCabe KE, Bartakova A, Delaney J, Pizzo DP, Newbury RO, Varner JA, Schlaepfer DD and Stupack DG: Integrin α4 enhances metastasis and may be associated with poor prognosis in MYCN-low neuroblastoma. PLoS One. 10:e01208152015. View Article : Google Scholar
19	Lee S, Qiao J, Paul P and Chung DH: Integrin β1 is critical for gastrin-releasing peptide receptor-mediated neuroblastoma cell migration and invasion. Surgery. 154:369–375. 2013. View Article : Google Scholar : PubMed/NCBI
20	Cheresh DA, Pierschbacher MD, Herzig MA and Mujoo K: Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 102:688–696. 1986. View Article : Google Scholar : PubMed/NCBI
21	Ohkawa Y, Miyazaki S, Miyata M, Hamamura K and Furukawa K and Furukawa K: Essential roles of integrin-mediated signaling for the enhancement of malignant properties of melanomas based on the expression of GD3. Biochem Biophys Res Commun. 373:14–19. 2008. View Article : Google Scholar : PubMed/NCBI
22	Dippold WG, Knuth A and Meyer zum Büschenfelde KH: Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 44:806–810. 1984.PubMed/NCBI
23	Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D and Rokita H: The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett. 281:171–182. 2009. View Article : Google Scholar : PubMed/NCBI
24	Marcinkiewicz C, Weinreb PH, Calvete JJ, Kisiel DG, Mousa SA, Tuszynski GP and Lobb RR: Obtustatin: A potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res. 63:2020–2023. 2003.PubMed/NCBI
25	Lin K, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, Lee WC, Hammond CE, Kalkunte S, Chen LL, et al: Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem. 42:920–934. 1999. View Article : Google Scholar : PubMed/NCBI
26	Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI and Laug WE: alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer. 98:690–697. 2002. View Article : Google Scholar : PubMed/NCBI
27	Gomes N, Vassy J, Lebos C, Arbeille B, Legrand C and Fauvel-Lafeve F: Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: Effects of alphavbeta3 and alphaIIbbeta3 antagonists. Clin Exp Metastasis. 21:553–561. 2004. View Article : Google Scholar
28	Horwacik I, Kurciński M, Bzowska M, Kowalczyk AK, Czaplicki D, Koliński A and Rokita H: Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a. Int J Mol Med. 28:47–57. 2011.PubMed/NCBI
29	Horwacik I, Golik P, Grudnik P, Kolinski M, Zdzalik M, Rokita H and Dubin G: Structural basis of GD2 ganglioside and mimetic peptide recognition by 14G2a antibody. Mol Cell Proteomics. 14:2577–2590. 2015. View Article : Google Scholar : PubMed/NCBI
30	Lew M: Good statistical practice in pharmacology. Problem 2. Br J Pharmacol. 152:299–303. 2007. View Article : Google Scholar : PubMed/NCBI
31	Seguin L, Desgrosellier JS, Weis SM and Cheresh DA: Integrins and cancer: Regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25:234–240. 2015. View Article : Google Scholar : PubMed/NCBI
32	Young SA, Graf R and Stupack DG: Neuroblastoma integrins. Neuroblastoma. Hiroyuki S: InTech Press; Rijeka, Croatia: pp. 189–216. 2013
33	Wu L, Bernard-Trifilo JA, Lim Y, Lim ST, Mitra SK, Uryu S, Chen M, Pallen CJ, Cheung NK, Mikolon D, et al: Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene. 27:1439–1448. 2008. View Article : Google Scholar
34	Hsu WM, Che MI, Liao YF, Chang HH, Chen CH, Huang YM, Jeng YM, Huang J, Quon MJ, Lee H, et al: B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β₁ integrin signaling in neuroblastoma. Am J Pathol. 179:1394–1404. 2011. View Article : Google Scholar : PubMed/NCBI
35	Leblond P, Dewitte A, Le Tinier F, Bal-Mahieu C, Baroncini M, Sarrazin T, Lartigau E, Lansiaux A and Meignan S: Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction. Anticancer Drugs. 24:818–825. 2013. View Article : Google Scholar : PubMed/NCBI
36	Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM and Cheresh DA: Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 155:459–470. 2001. View Article : Google Scholar : PubMed/NCBI
37	Rozzo C, Chiesa V, Caridi G, Pagnan G and Ponzoni M: Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer. 70:688–698. 1997. View Article : Google Scholar : PubMed/NCBI
38	Momic T, Katzehendler J, Benny O, Lahiani A, Cohen G, Noy E, Senderowitz H, Eble JA, Marcinkiewicz C and Lazarovici P: Vimocin and vidapin, cyclic KTS peptides, are dual antagonists of α1β1/α2β1 integrins with antiangiogenic activity. J Pharmacol Exp Ther. 350:506–519. 2014. View Article : Google Scholar : PubMed/NCBI
39	Cagnoni AJ, Pérez Sáez JM, Rabinovich GA and Mariño KV: Turning-off signaling by siglecs, selectins, and galectins: Chemical inhibition of glycan-dependent interactions in cancer. Front Oncol. 6:1092016. View Article : Google Scholar : PubMed/NCBI
40	Yoo BH, Masson O, Li Y, Khan IA, Gowda PS and Rosen KV: Anoikis of colon carcinoma cells triggered by β-catenin loss can be enhanced by tumor necrosis factor receptor 1 antagonists. Oncogene. 34:4939–4951. 2015. View Article : Google Scholar
41	Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG and Golubovskaya VM: Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle. 9:1005–1015. 2010. View Article : Google Scholar : PubMed/NCBI
42	Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, et al: Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell. 2:377–386. 2002. View Article : Google Scholar : PubMed/NCBI
43	Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG and Golubovskaya VM: N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem. 282:12503–12516. 2007. View Article : Google Scholar : PubMed/NCBI
44	Cagnet S, Faraldo MM, Kreft M, Sonnenberg A, Raymond K and Glukhova MA: Signaling events mediated by α3β1 integrin are essential for mammary tumorigenesis. Oncogene. 33:4286–4295. 2014. View Article : Google Scholar
45	Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, et al: Antagonizing integrin β3 increases immunosuppression in cancer. Cancer Res. 76:3484–3495. 2016. View Article : Google Scholar : PubMed/NCBI